Mucous Membrane Decontamination Market Size & Share, by Drug Class (Antibiotics, Corticosteroids, Anti-Inflammatory Drug, Monoclonal Antibodies); Product Type (Alcohol, Non-Alcohol Based); Administration (Injectable, Oral, Topical); Distribution Channel (Drug Store, Online, Retail, Hospital Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4189
  • Published Date: Feb 23, 2023
  • Report Format: PDF, PPT

Companies Dominating the Mucous Membrane Decontamination Landscape

top-features-companies
    • Astellas Pharma Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Bausch Health Companies Inc.
    • Genentech, Inc.
    • Lipidor AB
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Sun Pharmaceutical Industries Limited
    • EPI Health, LLC
    • Mölnlycke Health Care AB
    • Reckitt Benckiser Group plc

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Astellas Pharma Inc. announced its global strategic collaboration with Sutro Biopharma, Inc. along with licensing agreement to improvise the development procedure of novel immunostimulatory antibody-drug conjugates shortly known as iADCs.

  • Sun Pharmaceutical Industries Limited and its entirely owned subsidiaries launched an oral drug, Bempedoic Acid, under the brand name Brillo in India which focuses on low-density lipoprotein cholesterol to be decreased.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4189
  • Published Date: Feb 23, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing inclination of global population toward personal hygiene and higher prevalence of post-surgical wound infection are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 15% over the forecast period, i.e., 2023-2035.

Lack of awareness of the skin and autoimmune diseases are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Bausch Health Companies Inc., Genentech, Inc., Lipidor AB, Pfizer Inc., Merck & Co., Inc., Sun Pharmaceutical Industries Limited, EPI Health, LLC, Mölnlycke Health Care AB, and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue-generating capacity as well as the new products being launched into the market by the company.

The market is segmented by drug class, product type, administration, distribution channel, and by region.

The oral segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying